Compositions and methods for inhibiting expression of Nav1.8 gene

US7582745B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Dinah Wen-Yee Sah · Boston, US
• Maria Frank-Kamenetsky · Brookline, US
• Anke Geick · Bayreuth, DE
• Philipp Hadwiger · Kulmbach, DE
• Ingo Roehl · Memmelsdorf, DE
• Pamela Tan · Kulmbach, DE
• Hans-Peter Vornlocher · Bayreuth, DE

Key dates

• Filing date: Nov 3, 2006
• Grant date: Sep 1, 2009
• Expiry date: Nov 3, 2026

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/3515
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Nav1.8 gene (Nav1.8 gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Nav1.8 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Nav1.8 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Nav1.8 gene gene in a cell.